Cancer Conference Update: A Multimedia Review of Key Presentations from the 2016 American Society of Hematology Annual MeetingAbstracts 471, 474: Maintenance lenalidomide in patients with DLBCL
1:47 minutes.
TRANSCRIPTION:
DR FLOWERS: So these are 2 very provocative approaches that I think are interesting to look at for patients, particularly elderly patients with diffuse large B-cell lymphoma and patients who are not eligible for transplantation. The first abstract, presented by Catherine Thieblemont, looked at elderly patients with diffuse large B-cell lymphoma who received R-CHOP as their standard of care. And then patients were randomized then to go on and receive either lenalidomide maintenance versus observation. And with a median follow-up of about 40 months in the trial as a whole, the progression-free survival was not reached in the group that received lenalidomide maintenance. In this case, maintenance was given at 25 mg given 21 out of 28 days. And the group that received observation had a progression-free survival of about 68 months. And so this is an approach that I think, with additional data, additional follow-up on these patients and publications of this trial, is something that should be considered for older patients with diffuse large B-cell lymphoma, particularly since this patient population is one where, when they relapse, autologous stem cell transplant may not be an option as a curative approach. DR LOVE: So again, is this something that motivates you to think about it outside a trial setting? DR FLOWERS: Not quite yet. I’d like to see the publication first. But once the publication is available, I think this is an approach that should be considered for elderly patients with diffuse large B-cell lymphoma, particularly since autotransplant may not be an option for them in the future. |